San Diego’s KOGO has a short news piece on tirzepatide coming out of shortage, and its focus is on...
Getting away from GLP-1s, Pharmaceutical Executive features CEO Scott Brunner and Chief Advocacy Officer Tenille Davis in a video interview discussing “how compounded medications differ from commercially available drugs in terms of their manufacturing process, quality standards, and more.”
“Advantages & Disadvantages of Using Compounded Medications” includes the transcript, for those who prefer to read rather than watch.
